Mylan Prepared To Produce Tamiflu in Response to Potential Global Public Health Need

Oct 20, 2005, 01:00 ET from Mylan Laboratories Inc.

    PITTSBURGH, Oct. 20 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc.
 (NYSE:   MYL) today confirmed that the Company is prepared to produce
 significant volumes of Tamiflu, a pharmaceutical product produced by Roche
 Holdings AG.  Tamiflu, which is used to treat flu symptoms, is in high demand
 based on global concerns over a potential avian flu pandemic.  Mylan was
 contacted by United States Senator Charles Schumer, D-N.Y., and the company
 intends to immediately begin working with political leaders, the United States
 Food and Drug Administration and Roche to respond to this global health
     Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer.
 "Mylan is uniquely positioned to respond to this need for increased production
 of Tamiflu.  We have always structured our manufacturing capacity to be able
 to rapidly respond to urgent needs such as this one and we stand ready to
 contribute to the production of this important medication."
     About Mylan Laboratories
     Mylan Laboratories Inc. is a leading pharmaceutical company with three
 principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc.
 and UDL Laboratories, Inc., that develop, license, manufacture, market and
 distribute an extensive line of generic and proprietary products.
     This press release includes statements that constitute "forward-looking
 statements," including with regard to production of Tamiflu.  These statements
 are made pursuant to the safe harbor provisions of the Private Securities
 Litigation Reform Act of 1995.  Because such statements inherently involve
 risks and uncertainties, actual future results may differ materially from
 those expressed or implied by such forward-looking statements.  Factors that
 could cause or contribute to such differences include, but are not limited to:
 risks inherent in licensing negotiations; unexpected regulatory or other
 delays; the possible negative effects of any interruption or delay in the
 manufacture of the product; dependence on third parties for an adequate supply
 of the active ingredient; and the other risks detailed in the Company's
 periodic filings with the Securities and Exchange Commission. The Company
 undertakes no obligation to update these statements for revisions or changes
 after the date of this release.

SOURCE Mylan Laboratories Inc.